Recommendation ID

The Committee considered that rigorous data collection is needed on the life-extending benefits of lenalidomide when used in people with multiple myeloma who have received two or more prior therapies.

Any explanatory notes
(if applicable)

Source guidance details

Comes from guidance
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Date issued
June 2009

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 01/06/2019